Cytyc announces two-for-one stock split
This article was originally published in Clinica
Women's health company Cytyc has announced a two-for-one stock split to take effect on or around January 28. All shareholders of record on January 14 will receive an additional share for each share owned. On completion of the stock split, Cytyc will have about 36 million shares. Shares in the company rose by around $4.50 to $60.50.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.